"Designing Growth Strategies is in our DNA"

Hepatitis C Testing Market Size, Share and Global Trend, By Technique ( Immunoassays, Polymerase Chain Reaction ( PCR ), Others), By Test ( Antibody Test, Genotype Tests, Viral Load Test), By End User ( Hospital-based Laboratories, Stand-alone Laboratories, Others), and Geography Forecast till 2026

Region : | Published Date: Upcoming | Report ID: FBI100461| Status : Upcoming

 

KEY INDUSTRY INSIGHTS

Hepatitis C is a liver disease caused by the hepatitis C virus. There are mainly three types of hepatitis found namely hepatitis A, B, and C. Each is caused by different viruses. Hepatitis C is caused by the hepatitis C virus (HCV) which is commonly prevalent over the other 2 forms of hepatitis. Hepatitis C is transmitted through direct contact with infected body fluids, majorly through injection, drugs use and sexual contact. Recently, in 2013, OraSure Technologies, Inc., launched OraQuick HCV antibody mouth swab test, which produces results in 20 minutes.


Rising prevalence of liver cancer, improving diagnosis rates for hepatitis C virus in emerging countries, and increasing number of government programs spreading awareness regarding hepatitis C testing are some of the major factors driving the growth of the global hepatitis C testing market. Hepatitis C test has been made mandatory for the organ donation, this is a major driver for the global hepatitis C testing market.


To get information on various segments, share your queries with us


Inadequate insurance and reimbursement policies for hepatitis C testing market and lack of awareness about the rapid hepatitis C testing in developing countries are some of the factors restraining the growth of the global hepatitis C testing market during the forecast period of 2019-2026.


Key Players Covered


Some of the major companies that are present in the global Hepatitis C Testing market are OraSure Technologies, Inc., Abbott, Siemens Healthcare Private Limited, Bio-Rad Laboratories, Inc., Bayer AG, QIAGEN, Thermo Fisher Scientific Inc., BioGenex, AccuQuick, and others.


Segmentation


























Segmentation



 Details



By Technique



·         Immunoassays


·         Polymerase Chain Reaction (PCR)


·         Others



By Test



·         Antibody Test


·         Genotype Tests


·         Viral Load Test



By End User



·         Hospital-based Laboratories


·         Stand-alone Laboratories


·         Others



By Geography



·         North America (USA and Canada)


·         Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)


·         Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)


·         Latin America (Brazil, Mexico and Rest of Latin America)


·         Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)



In 2018, Hepatitis C antibody test accounted for the highest share of the test segment in the global hepatitis C testing market due to increased demand and better clinical efficiency. The segment is projected to continue its dominance in the market share during the forecast period.



 Key Insights


Pricing Analysis by Key Regions


Reimbursement Scenario for Key Countries


Recent industry developments such as partnerships, mergers, and acquisitions


Regional Analysis


The global hepatitis C testing market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for Hepatitis C testing in 2018. North America accounted for the largest share of the global hepatitis C testing market in 2018, owing to the increasing prevalence of hepatitis C. Asia-Pacific and Latin America are anticipated to grow at a comparatively higher CAGR during the forecast period, owing to the growing awareness of advanced products for hepatitis C testing in emerging countries, the increasing patient population suffering from hepatitis C.


Key Industry Developments     



  • In April 2019, Access Bio Inc. and Atomo Diagnostics announced the development of the rapid diagnostic test (RDT) for screening for hepatitis C virus (HCV). It is expected that the tests will be made commercially available by end of this year.

  • In March 2019, Gilead Sciences, Inc., announced the HepConnect Initiative to Reduce Hepatitis C Infections in Greater Appalachia.

  • In September 2018, London Drugs took initiative towards the innovative and potentially life-saving hepatitis C screening program which is been launched at five London Drugs locations in the Lower Mainland.


 


Hepatitis C Testing Market  Size, Share and Global Industry Trend Forecast till 2026
  • PDF
  • 2018
  • 2014-2017

    CHOOSE LICENSE TYPE

  • 4850
    6850
    8850

Healthcare Clients

SUANFARMA
lpsos
Bio-Rad
DUPONT
baxter
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info.
X